News

CGDV: Strong Track Record And Unique Positioning Make It A Buy (NYSEARCA:CGDV)

1 Mins read

This article was written by

I manage portfolios and write about the world. Long signal, short noise. Macro strategist and investment advisor from Southern California. You can also find me on YouTube and Substack under my name; my weekly newsletter is called The Macro Obsession.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of CGDV, SPY, MSFT, META, LLY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Read the full article here

Related posts
News

ZTR: Hybrid Portfolio With Utility Tilt At A Deep Discount (NYSE:ZTR)

1 Mins read
This article was written by Follow Nick Ackerman is a former financial advisor using his experience to provide coverage on closed-end funds…
News

IJT ETF: Why The Tide May Turn For Small-Cap Growth In 2026 (NASDAQ:IJT)

1 Mins read
This article was written by Follow The Sunday Investor is focused exclusively on U.S. Equity ETFs. He has a strong analytical background,…
News

Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript

1 Mins read
Follow Play Earnings CallPlay Earnings Call Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *